Yimitasvir - HEC PharmAlternative Names: DAG 181; Yimitasvir phosphate - HEC Pharm
Latest Information Update: 20 Jan 2017
At a glance
- Originator HEC Pharm
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis C